PRESS RELEASE published on 02/06/2024 at 16:00, 2 years 8 months ago Cantabio Pharmaceuticals Awarded Major Grant from The Michael J. Fox Foundation for the Development of a novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease Cantabio Pharmaceuticals, Inc. receives major grant from MJFF for the development of DJ-1 replacement therapy aimed at treating Parkinson's disease by increasing DJ-1 levels in patients and preventing disease progression Precision Medicine Cantabio Pharmaceuticals MJFF Grant DJ-1 Replacement Therapy Parkinson's Disease
Published on 11/05/2026 at 15:20, 11 minutes ago MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors
Published on 11/05/2026 at 14:31, 1 hour ago First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile
Published on 11/05/2026 at 14:25, 1 hour 6 minutes ago Polaris Renewable Energy Announces Q3 2026 Results
Published on 11/05/2026 at 14:20, 1 hour 11 minutes ago Polaris Renewable Energy Declares Quarterly Dividend
Published on 11/05/2026 at 14:15, 1 hour 16 minutes ago Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook
Published on 11/05/2026 at 15:10, 20 minutes ago Center for Creative Leadership Names Patrick Mullane President and Chief Executive Officer
Published on 11/05/2026 at 14:58, 32 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/05/2026 at 15:01, 29 minutes ago Chiffre d'Affaires du 1er semestre de l'exercice 2026/2027
Published on 11/05/2026 at 10:16, 5 hours 14 minutes ago Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Published on 11/05/2026 at 10:16, 5 hours 14 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%